66 results about "Ivermectinum" patented technology

Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.

The invention discloses a method for detecting the residual quantity of ivermectin in sheep muscle tissues by using a liquid chromatograph/mass spectrometer with doramectin as an internal standard substance. The method comprises the following steps: extracting ivermectin residual in the sheep muscle tissues with acetonitrile as an extraction solvent, adopting an impurity adsorption and solid phase extraction mode, adopting an alkaline alumina column as a solid phase extraction column, introducing acetonitrile, eluting, and collecting all obtained eluate. The method solves the problems of complex extraction and purification processes and high detection limit of traditional detection methods, realizes enrichment and purification of ivermectin residual in the sheep muscle tissues, improves the detection sensitivity, repeatability and accuracy, and is suitable for batch sample detection.

The invention relates to a medium for producing ivermectin by fermenting streptomyces avermitilis and a fermenting method. By adding substances such as formula molasses, formula earthworm powder and the like into the medium for optimizing the medium formula, and corresponding optimizing the fermenting technology, the medium and the cultivation method for enabling ivermectin fermentation unit to be stable are provided, the average fermentation unit of ivermectin is 6000 mu g/mL or more and is improved by 20% or more compared with domestic conventional fermentation level. The fermentation period of ivermectin is averagely shortened by 10 h or more, so that the problem is effectively solved that conventional fermentation technology is high in cost; and the environmental influence on sources of raw materials and auxiliary materials is furthest reduced, and the raw materials and the auxiliary materials are guaranteed to be sufficiently supplied, so that the stable efficient production of ivermectin is realized.

The invention relates to a preparation method of ivermectin. The ivermectin is prepared by taking an abamectin B2 component as a raw material and removing 23-position sulfonyl hydrazone of the abamectin B2 through reduction, and the process comprises the following steps: (1) protecting 4''-position hydroxyl and 5-position hydroxyl of the abamectin B2 with allyl carbonate; (2) oxidizing 23-position hydroxyl of the abamectin B2 into keto carbonyl; (3) converting the 23-position keto carbonyl of the abamectin B2 with organic sulfonyl hydrazine into hydrazone, thus generating the 23-position sulfonyl hydrazone of the abamectin B2; and (4) reducing with hydroborate to remove the 23-position sulfonyl hydrazone of the abamectin B2, and simultaneously removing the 4''-position protecting group and the 5-position protecting group to obtain the ivermectin. The total yield of the reaction is up to 67-72%. According to the invention, the ivermectin is prepared by taking the abamectin B2 component as the raw material, the utilization range of the abamectin B2 is widened, the cost of the ivermectin is reduced, the preparation conditions are mild, the yield is high, and the use of virulent tributyltin hydride Bu3SnH is avoided. Thus, the invention is suitable for industrial production.

The invention relates to a macrolide compound as well as a preparation method and application thereof, in particular a modified ivermectin derivative as well as a preparation method and application thereof. General formulas (I) (II) of the compound of the macrolide derivative and salt thereof are as shown in the specification. The compound disclosed by the invention is efficient, safe, stable, wide in spectrum and low in toxicity, and has an excellent agricultural insecticidal and acaricidal activity as well as an activity of killing parasites of domestic animals and medical uronema, wherein n represents 0, 1, 2, 3, 4, 5, 6 or 7; X is either N or O; Y represents Cl<->; Z is either N or O; R1 and R2 are selected from H and C1-C4 alkyl; or ZR1R2 is selected from the following structures as shown in the specification.

The invention discloses a veterinary compound pharmaceutical composition containing albendazole and ivermectin, and relates to the field of veterinary drug technical preparation. The veterinary compound pharmaceutical composition comprises the following components: albendazole, ivermectin, sulfamonomethoxine, lactobacillus and soluble starch. The veterinary antiparasitic pharmaceutical composition is convenient to use, is mutually synergistic, has broad spectrum of insect resistance and good insect-resistant effect, can increase gastric motility, increases feed intake, and is in favor of the growth of livestock. The pharmaceutical compound of the invention can be a dry suspension, can be directly added in an automatic drinking device in proportion, is convenient to use, and has wide application prospects.

The invention discloses a pharmaceutical composition for treating chicken coccidiosis. The pharmaceutical composition is prepared from the following components by weight: 0.25 to 2.5 parts of ivermectin, 2.5 to 25 parts of antifeverile dichroa root extract, 15 to 25 parts of astragalus extract, 15 to 25 parts of dark plum extract, 10 to 15 parts of hairyvein agrimony extract and 500 parts of purified attapulgite. The invention also provides a preparation method for the pharmaceutical composition. The invention has the following advantages: the pharmaceutical composition provided by the invention has an anticoccidial index of more than 195 and is composed of both traditional Chinese medicines and western medicines; and an adjuvant material in an oral preparation is attapulgite, so slow release effect is exerted, residues are hardly left, so the pharmaceutical composition has obvious advantages. According to results of in-vitro anticoccidial sporlating test and artificial treatment effect test of chicks infected with coccidia, the traditional Chinese medicine composition provided by the invention has anticoccidial effect; so the composition facilitates further confirmation of the application scope of a compound medicine, provides related enterprises with a novel approach to develop high-quality products, broadens novel application fields of medicine resources, lays a good foundation for research and development of a novel anticoccidial medicine and is of obvious significance.

The invention discloses an ivermectin controlled-release capsule and a preparation method and application thereof. The ivermectin controlled-release capsule comprises, by mass, 0.1-1% of ivermectin raw material, 20-60% of water-soluble carrier and 30-70% of enteric-soluble wrapping material, the water-soluble carrier is one or multiple of hydroxypropyl-beta-cyclodextrin, methyl-beta-cyclodextrin,HPMC, PVP, PEG, poloxamer 188, mannitol, D-alpha-tocopherol PEG 1000 succinate, cholate/phospholipid mixed micelle, polyethylenediamine dendritic polymer, phospholipid or cholesterol, and the enteric-soluble wrapping material is one or multiple of hydroxypropyl methyl cellulose phthalic acid, acrylic resin II, acrylic III, cellulose acetate phthalate, polyethylene diacetate phthalate or hydroxypropyl methyl cellulose acetate succinate. The ivermectin controlled-release capsule has the advantage of outstanding acid resistance, enables drug to reach intestinal tracts to be disintegrated and released, remarkably improves bioavailability and has remarkable treatment effect.

The invention discloses an albendazole and ivermectin premix as well as a preparation method and application thereof, and relates to the technical field of veterinary drugs. The albendazole and ivermectin premixing agent is prepared from the following components in percentage by mass: 5.5 to 6.5 percent of albendazole, 0.2 to 0.3 percent of ivermectin, 4 to 6 percent of activated carbon, 55 to 65 percent of polyethylene glycol and 25 to 35 percent of glyceryl monostearate. The preparation method comprises the following steps: heating, melting, emulsifying and stirring the components to form a medicine suspension, and carrying out spray drying and condensation on the medicine suspension to form spherical particles. According to the albendazole and ivermectin premixing agent provided by the invention, the dosage of albendazole and ivermectin is controlled, specific auxiliary materials are selected, albendazole and ivermectin are dispersed in molten liquid of the auxiliary materials, and spherical fine particles are formed through spray drying and condensation, so that the albendazole and ivermectin premixing agent is prepared. The albendazole and ivermectin premixing agent prepared by the invention can be uniformly mixed and is good in dispersity.

The invention discloses a novel ivermectin hapten. The novel ivermectin hapten is obtained through reacting with carboxymethoxylamine hemihydrochloride at the C4-OH position of ivermectin and substituting hydroxyl on C4 with carboxymethyl hydroxyamino; the derivative is coupled with carrier protein to be used as an immunogen, and can be used for preparing a monoclonal antibody for resisting an abamectin type drug. The invention further discloses one broad-spectrum monoclonal antibody for resisting the abamectin type drug; the monoclonal antibody can be used for simultaneously and specificallyidentifying abamectin, ivermectin, eprinomectin and emamectin; and an enzyme immunoassay method and a kit, which are established by utilizing the monoclonal antibody are suitable for detecting residues of the abamectin type drug in animal tissues and have the advantages of sensitivity in detection, high accuracy, good precision and the like.

The invention belongs to the technical field of an anti-parasitic drug, and particularly relates to an application of a composition containing ivermectin and levamisole hydrochloride to preparation ofa veterinary anti-parasitic drug, a transdermal solution of the veterinary anti-parasitic drug and a preparation method of the transdermal solution. The transdermal solution comprises components in parts by volume as follows: 20-50 parts of isopropanol, 10-40 parts of glycerol, 10-30 parts of absolute ethyl alcohol, 5-20 parts of dimethyl sulfoxide and 2-6 parts of azone; the content of ivermectin is 0.3-1 g per 100 mL of solution, and the content of levamisole hydrochloride is 5-15 g per 100 mL of solution. According to the invention, ivermectin and levamisole hydrochloride are combined, a synergistic effect is realized by simultaneous use of ivermectin and levamisole hydrochloride, and an anti-parasitic spectrum is improved; and meanwhile, with adoption of a transdermal absorption dosage form, toxic and side effects caused by correlation of the drug and the dosage are reduced, and a simultaneous internal and external anti-parasitic effect of the preparation is realized.

The invention discloses an inclusion complex formed by ivermectin and cyclodextrin and a preparation method of the inclusion complex. The inclusion complex is prepared by raw ivermectin and beta-cyclodextrin according to the mass ratio of 1:10-1:25. The preparation method includes: dissolving the raw ivermectin into an organic solvent, evenly spraying onto the pasty cyclodextrin, well mixing through colloid grinding, and feeding nitrogen and drying to obtain the inclusion complex. The inclusion complex and the preparation method of the inclusion complex have the advantages that the cavity structure of the cyclodextrin is used to wrap the ivermectin so as to increase the stability and water solubility of the ivermectin, the ivermectin can be prepared into a water solution, and consumption of the organic solvent is reduced.

Disclosed herein are pharmaceutical compositions and methods for the treatment of anterior blepharitis and posterior blepharitis which may be of primary origin and not secondary to other factors such as infections, infestations or rosacea. The composition comprises Ivermectin in the range of about 0.001% to 20% by weight of the total composition. Topical administration of said compositions precisely to the eyelid margin provides therapeutic benefit to patients suffering from anterior blepharitis and posterior blepharitis.

The invention relates to a veterinary anthelmintic, and particularly relates to a veterinary albendazole/ivermectin dry suspension with using convenience and significant drug effects. The dry suspension is prepared by steps of stirring 0.1-0.2 part of ivermectin and 2-4 parts of sodium carboxymethylcellulose and mixing, adding 2-4 parts of a flavoring agent after the powder is mixed uniformly, and mixing uniformly again; stirring 5-15 parts of albendazole and 10-20 parts of sodium chloride and mixing, adding 5-10 parts of sodium citrate after the powder is mixed uniformly, and mixing uniformly again; adding the former into the latter through an equivalent increment method, and stirring uniformly; adding the balance of other auxiliary material, and further uniformly stirring and mixing; and subpackaging to obtain the finished product. The other auxiliary material is soluble starch or microcrystalline cellulose. The dry suspension can be proportionally added in an automatic drinker directly for use, thus facilitating all-round dosing in a large-size livestock farm. The dry suspension avoids the toxic and side effect caused by non-uniform feed mixing, and is more convenient to use. The drug effect is remarkably enhanced, and the cost is obviously lowered in comparison with the prior art. The dry suspension has a wide application prospect.

The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

A water-soluble ivermectin oral liquid for veterinary use and a preparing method thereof are disclosed. Each 1000 mL of the oral liquid comprises 0.1-2 g of ivermectin, 1-20 mL of ethyl acetate, 50-150 mL of Tween-80, 1-10 g of sodium hydrogen phosphate, 1-10 g of sodium dihydrogen phosphate and 0.001-1 g of thiomersal, with the balance being water. The oral liquid adopts the water as a solvent, the ivermectin is low in solubility in water, but a solution can be uniform through adding the water after the ethyl acetate and the tween-80 which are high in dose are utilized to promote solution of the ivermectin, and therefore the ivermectin oral liquid is uniform, stable and long in shelf life, and is nonirritant to mouth mucosa, lower in production cost and good in absorption when being compared to oil oral liquids.

Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.

The invention discloses an albendazole ivermectin enteric-coated sustained-release pellet. The albendazole ivermectin enteric-coated sustained-release pellet is prepared by taking classical anthelmintic drug combination albendazole ivermectin powder (10% albendazole and 0.2% ivermectin) as an active ingredient and adding proper auxiliary materials, and comprises a pellet core layer and an enteric-coated layer, wherein the weight percentage of the pellet core layer and the enteric-coated layer is as follows: 70-85% of pellet core and 15-30% of enteric-coated layer. The invention further discloses a preparation method and application of the enteric-coated sustained-release pellet. The enteric-coated sustained-release pellet disclosed by the invention is used for expelling and killing in-vivo and in-vitro parasites such as pig nematodes, trematodes, tapeworms, mites and lice. The albendazole and the ivermectin both have certain toxicity, the bioavailability of the common albendazole ivermectin powder orally taken by pigs is only 40-50%, and toxic and side effects are often caused if an effective dose is expected in clinical use; the enteric-coated sustained-release pellet disclosed by the invention can release a large amount of drugs only in an intestinal environment with a pH value of 6.8 or above, thus reducing the damages of an acidic stomach environment to the drugs; amd the drugs are stably and slowly released in the intestinal tract, the maintenance time of an effective blood concentration is prolonged, the bioavailability is 80% or above, the clinical dosage can be reduced by 30% or above, the safety is greatly improved, and the application prospect is wide.